Conclusion: The WHO classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies.
T

HE SOCIETY FOR Hematopathology and the Euro-
pean Association of Hematopathologists jointly developed a classification of hematologic neoplasms for the World Health Organization (WHO). A steering committee composed of members of both societies was formed, and 10 committees were assigned the task of arriving at a consensus list of myeloid, lymphoid, and histiocytic neoplasms, with descriptions and criteria for diagnosis. A new classification for lymphoid neoplasms was recently proposed, 1 and the goals of the WHO project were to update and revise that classification, with input from additional experts in order to broaden the consensus, and to extend the principles of disease definition and consensus building to the myeloid and histiocytic neoplasms. More than 50 pathologists from around the world were involved in the project, which began in 1995. Proponents of all major lymphoma and leukemia classifications agreed that if a reasonable consensus emerged from this effort, they would accept the WHO classification of hematologic malignancies as the standard.
The proposed WHO classification of hematologic malignancies stratifies neoplasms primarily according to their lineage: myeloid neoplasms (Table 1) , lymphoid neoplasms (Tables 2 and 3) , mast cell disorders (Table 4) , and histiocytic neoplasms (Table 5 ). Variants and subtypes of selected neoplasms are listed in Tables 6 through 15 . Within each category, distinct diseases are defined according to a combination of morphology, immunophenotype, genetic features, and clinical syndromes. The relative importance of each criterion differs among the neoplasms, and there is no one gold standard for classification of all hematologic malignancies. The goal was to define disease entities that could be recognized by pathologists and that have clinical relevance.
To ensure that the proposed classification would be of maximal use to oncologists, the steering committee invited expert hematologists and oncologists to form a clinical advisory committee (CAC), with American and European co-chairs. The charge to the CAC was to review the proposed classification and advise the pathologists on its clinical utility. More than 40 hematologists and oncologists from around the world agreed to participate. The proposed classification was circulated, and all participants were invited to submit topics and questions for discussion. A meeting was held in November 1997, at Airlie House, VA, involving the CAC, all pathologists involved in the WHO committees, and the executive committees of the two hematopathology societies.
The meeting was organized around a series of questions developed from those submitted by CAC members and posed by the pathologists. Only controversial issues were discussed; diseases were accepted as previously defined if there were no new questions or data. Only lymphoid and myeloid neoplasms were discussed at the meeting; histiocytic and mast cell tumors were not considered. Participants were invited to present data relevant to each question, and open discussion followed. At the end of each session, the clinicians were asked to arrive at a consensus regarding each question (as well as other issues raised at the meeting); if necessary, a show of hands was taken as a vote. After the meeting, participants were polled to resolve residual questions; several additional meetings of the pathology steering committee and the CAC co-chairs were held for the same purpose. The final classification will be published under the auspices of the WHO. 2 
MYELOID NEOPLASMS
Despite advances in the understanding of genetic factors in the biology of the myeloid neoplasms, particularly the acute leukemias, the classification of these disorders has not been recently updated. Thus, discussion of these disorders generated considerable controversy. At several subsequent meetings of pathologists and the clinical co-chairs, a consensus on the classification emerged. The following summary includes issues raised at the CAC meeting and resolutions achieved subsequently.
In the French-American-British (FAB) classification, three main categories of myeloid neoplasms are recognized: acute myeloid leukemias, myelodysplastic syndromes, and myelo- Abbreviation: AML, acute myeloid leukemia. *Acute lymphoid leukemias are included under lymphoid neoplasms and in Table 6 . proliferative disorders. 3 The blast count, lineage commitment, and level of differentiation of the neoplastic cells are the major determinants of the categories recognized, using morphologic, cytochemical, and immunophenotypic features. Recently, genetic features (cytogenetic and molecular genetic), as well as other features, such as prior therapy and a history of myelodysplasia, have been shown to have a significant impact on the clinical behavior of these disorders, and these features do not always correlate perfectly with the FAB categories. Thus, a major focus of debate was how to integrate genetic and clinical features with morphology, cytochemistry, and immunophenotype into a classification that could be used by pathologists and have clinical relevance. A key issue, as with the lymphoid neoplasms, was to discriminate between disease entities and prognostic factors. Some genetic abnormalities seem to define distinct diseases, whereas others are prognostic factors within a given disease. Also debated was whether all diseases fit into one of the three major categories or whether additional broad categories are needed.
After discussion, it seemed that a paradigm similar to that adopted for the Revised European-American Lymphoma (REAL) classification could at least tentatively apply to the myeloid disorders; namely, a combination of morphology, immunophenotype, genetic features, and clinical features could be used to define distinct disease entities. The technology of genetic analysis is evolving rapidly, and it is likely that advances in this field will necessitate revisions to Tables 7 through 16 . Common entities are shown in boldface type.
Abbreviations: HTLV1ϩ, human T-cell leukemia virus; MALT, mucosaassociated lymphoid tissue; NK, natural killer.
*B-and T-/NK-cell neoplasms are grouped according to major clinical presentations (predominantly disseminated/leukemic, primary extranodal, predominantly nodal). Cutaneous mastocytosis Systemic mast cell disease (ϩ/Ϫ skin involvement) Systemic mast cell disease with associated hematologic disorder (ϩ/Ϫ skin involvement) Mast cell leukemia/sarcoma any current classification in the near future. The pathologists proposed four major groups of myeloid diseases: myeloproliferative diseases (MPDs), myelodysplastic/myeloproliferative diseases (MD/MPDs), myelodysplastic syndromes (MDSs), and acute myeloid leukemias (AMLs). Within the category of AML, four main groups are recognized: (1) AML with recurrent cytogenetic translocations; (2) AML with myelodysplasia-related features; (3) therapy-related AML and MDS; and (4) AML not otherwise specified.
Myeloproliferative Diseases
MPDs are clonal stem-cell disorders characterized by ''effective'' hematopoiesis that results in elevated peripheralblood levels of one or more cell lines and hepatosplenomegaly; the marrow is hypercellular with maturation and without dysplasia. Among the MPDs, the prototype is Philadelphia chromosome (Ph1)-positive (BCR/ABL ϩ ) chronic myelogenous leukemia (CML). The other accepted entities are polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Controversies within this group include the definitions and classification of juvenile myelomonocytic leukemia (JMML; also known as juvenile chronic myeloid leukemia and juvenile chronic myelomonocytic leukemia), chronic myelomonocytic leukemia (CMML), and atypical CML.
Should JMML be a separate category? Should it be classified as an MDS or an MPD? The CAC accepted the conclusions of the International Study Group for Pediatric MDS that JMML is a separate disorder, distinct from adult chronic myeloid or myelomonocytic leukemia. CAC members proposed that the term JMML be adopted. They favored including it in the MPDs; however, the pathologists recommended that a separate category be formed to include JMML and other disorders that combine features of myeloproliferative and myelodysplastic syndromes.
Should CMML be divided into MDS and MPD types? CMML has long been recognized as a disorder that has features of both myelodysplastic and myeloproliferative syndromes. Nearly half the patients present with low or normal neutrophil counts, multilineage marrow dysplasia, no organomegaly, and bone marrow morphology that resembles refractory anemia with excess blasts (RAEB) but with monocytosis. Other patients have marked neutrophilia, monocytosis, and splenomegaly. It has been debated whether this is really two diseases-one an MDS and the other an MPD. However, studies to date have shown no differences in cytogenetic abnormalities, oncogene mutations, in vitro colony growth patterns, or clinical outcome between the two types of CMML. It was the consensus at the meeting that CMML is one disease. The CAC concluded that CMML fits better in the MPD than in the MDS category, but after subsequent discussions, the pathologists recommended that it be included in a separate category, along with JMML, of disorders with both myeloproliferative and myelodysplastic features.
What should the nomenclature and category be for atypical CML (aCML)? Atypical CML was first recognized as a disease involving predominantly the neutrophil series and lacking Ph1 or the BCR/ABL translocation. It has dysplastic as well as proliferative features and often occurs with multilineage dysplasia. The prognosis is significantly worse than that for Ph1 ϩ CML. It is clear that it is clinically, genetically, and morphologically distinct from Ph1 ϩ CML; therefore, the term aCML is suboptimal, implying both a 
Acute Myeloid Leukemia and Myelodysplastic Syndrome
What blast count should define AML? According to the FAB standard, AML is defined by the presence of 30% blasts. However, recent studies have indicated that patients with 20% to 30% blasts (classified as RAEB in transformation) have a prognosis similar to that of patients with more than 30% blasts. Thus, there was a consensus that the blast count for the diagnosis of AML should be 20% and the RAEB in transformation category should be dropped.
Should cytogenetic/molecular categories of AML be recognized as distinct diseases? Several specific cytogenetic abnormalities in AML are associated with characteristic morphology and have distinctive clinical features. With the exception of promyelocytic leukemia/M3 with t(15;17), these genetic abnormalities do not correlate precisely with FAB categories. The consensus of the CAC was that these categories should be recognized as distinct entities within the classification. After discussion, the pathologists agreed that it would be possible to develop morphologic criteria for these categories that would permit them to be recognized, or at least suspected, by pathologists, who should then suggest confirmation by genetic analysis. The following specific categories will be defined: (1) AML with t(8;21)(q22;q22), AML1(CBF-alpha)/ETO; (2) acute promyelocytic leukemia (AML with t(15;17)(q22;q11-12) and variants, PML/RARalpha); (3) AML with abnormal bone marrow eosinophils (inv(16)(p13q22) or t(16;16)(p13;q22), CBF-beta/MYH11); and (4) AML with 11q23 (MLL) abnormalities. 
CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES
The specific morphologic features of these disorders will be described in the classification, 2 and these entities will be excluded from the FAB categories used for cases that lack these abnormalities. In addition, cases with these specific cytogenetic abnormalities with low blast counts, which in the past might have been diagnosed as MDS, will now be classified as AML.
Should multilineage dysplasia, prior MDS, and/or prior therapy be included in the classification of AML? Severe multilineage dysplasia, defined as the presence of dysplastic features in two or more cell lines, has been shown to be associated with poor outcome in AML. Similarly, AML arising in patients with a history of MDS also has a poor prognosis. Therapy-related leukemias secondary to alkylating-agent therapy are clearly different from many de novo acute leukemias; they are associated with characteristic cytogenetic abnormalities (3qϪ, Ϫ5, 5qϪ, Ϫ7, 7qϪ, ϩ8, ϩ9, 11qϪ, 12pϪ, Ϫ18, Ϫ19, 20qϪ, ϩ21, t(1;7), t(2;11), complex karyotypes) and a worse prognosis and often show multilineage dysplasia or are preceded by a hypoproliferative state with multilineage dysplasia, resembling MDS. Similar cytogenetic abnormalities are often seen in MDS not associated with prior therapy and in de novo acute leukemias, particularly in the elderly. It has been suggested that all of these disorders reflect similar genetic damage, which may be either environmental or iatrogenic. There was a consensus that the presence of multilineage dysplasia at the time of the diagnosis of acute leukemia, a history of myelodysplasia, and prior alkylating-agent therapy were all adverse prognostic factors, which may reflect a common pathogenesis. The committee concluded that multilineage dysplasia, a history of MDS, and a history of alkylating-agent therapy should be included in the classification of AML.
The specific cytogenetic abnormalities common to MDS, alkylating-agent-related AML, and poor-prognosis AML (3qϪ, Ϫ5, 5qϪ, Ϫ7, 7qϪ, ϩ8, ϩ9, 11qϪ, 12pϪ, Ϫ18, Ϫ19, 20qϪ, ϩ21, t(1;7), t(2;11), complex karyotypes) likely reflect a common pathogenesis of these lesions, distinct from that of other de novo AMLs. However, there was no consensus on the role of these abnormalities in defining disease entities within the classification. Our understanding of this issue will likely improve in the near future, necessitating a change in the major groupings. However, for the present, cytogenetic abnormalities indicative of poor prognosis should be recognized as prognostic factors within each category of AML.
Therapy with topoisomerase II inhibitors (epipodophyllotoxins and doxorubicin) is also associated with secondary leukemias, which are often myeloid but may be lymphoid. They typically show cytogenetic abnormalities associated with de novo AML-most commonly translocations involving 11q23 (MLL) but also occasionally t(8;21), inv(16), or t(15;17). These cases should also be recognized in the classification as distinct from alkylating-agent-related secondary leukemias.
Should refractory cytopenia with multilineage dysplasia be a separate category? MDSs are clonal stem-cell disorders characterized by ineffective hematopoiesis that results clinically in peripheral-blood cytopenias; the marrow is variably hypercellular, and patients show poor responses to chemotherapy and have an increased risk of progression to acute leukemia. Refractory anemia and refractory anemia with ring sideroblasts were defined in the FAB classification as having dysplasia largely restricted to the erythroid line. Recent studies have shown that patients with MDS and less The proposed WHO classification of lymphoid neoplasms adopts the REAL classification, proposed by the International Lymphoma Study Group. The REAL classification is based on the premise that a classification should attempt to define distinct disease entities, using all available information, including morphology, immunophenotype, genetic features, and clinical features. There is no single gold standard, and the importance of various criteria for both definition and diagnosis differs among different diseases. On the basis of 3 years of experience with the REAL classification and input from the committees, several changes were proposed for the WHO classification. These included changes in nomenclature, division of heterogeneous categories, and adoption of ''provisional'' entities as ''real.'' The proposed WHO classification recognizes B-cell neoplasms, T-cell/natural-killer (NK)-cell neoplasms, and Hodgkin's disease (HD). The T-and B-cell neoplasms were stratified into precursor, or lymphoblastic, neoplasms (acute lymphoblastic leukemia [ALL] and lymphoblastic lymphoma) and mature (peripheral) B-and T-cell neoplasms. The mature B-and T-cell neoplasms were informally grouped according to their major clinical presentations: predominantly disseminated/leukemic, primary extranodal, and predominantly nodal diseases. The pathologists sought input from the clinicians on these changes as well as on issues that remained controversial or problematic, such as grading of follicular lymphoma, how to define Burkitt-like lymphoma, subclassification of large B-cell lymphomas and mature T-cell lymphomas, and the desirability of clinical groupings of the non-Hodgkin's lymphomas.
Precursor Neoplasms
Should the FAB terms (L1, L2, L3) be retained? There was a consensus that the FAB terms are no longer relevant, since L1 and L2 morphology do not predict immunophenotype, genetic abnormalities, or clinical behavior. L3 is generally equivalent to Burkitt's lymphoma in leukemic phase and should be diagnosed as such.
Are lymphoblastic leukemias and lymphoblastic lymphomas a single disease with different presentations? There was a consensus that the precursor neoplasms presenting as solid tumors and those presenting with marrow and blood involvement are biologically the same disease with different clinical presentations. The presence of bone marrow and peripheral-blood involvement are principally prognostic factors/staging issues and not classification issues, although the biologic basis for the different clinical presentations is not fully understood. Most precursor lymphoid neoplasms present as leukemia; thus, it was agreed that the classification should retain the term ALL for the leukemic phase of precursor neoplasms of T and B types (Table 6) .
Should genetic abnormalities be included in the classification? Genetic abnormalities are important prognostic factors within precursor B lymphoblastic neoplasms (t(9;22)(q34; q11), BCR/ABL; 11q23, MLL; t(1;19)(q23;p13), E2A/PBX1; t(12;21)(p12;q22); ETV/CBF-alpha). Pathologists who attempt to diagnose these neoplasms should be familiar with the types and significance of genetic abnormalities that can be seen. Genetic analysis should form part of (or an addendum to) the pathology report whenever feasible (Table 6) .
Precursor Neoplasms: Summary. 
Mature B and T/NK Neoplasms
As for the precursor neoplasms, the proposed classification considers lymphomas and lymphoid leukemias of the same cell type as one disease with different clinical presentations or stages. For the mature B and T/NK neoplasms, this question is primarily relevant to B-cell chronic lymphocytic leukemia (CLL) and B-cell small lymphocytic lymphoma (SLL). Although patients in some locations may be seen by different physicians based on their presentation (eg, patients with peripheral-blood involvement [leukemias] are seen by hematologists and those with tissue involvement [lymphomas] are seen by oncologists), there was a consensus that the two diseases are biologically the same (Table 7) .
Follicular Lymphoma
Should the nomenclature be changed to follicular lymphoma? The WHO committee proposed to change the nomenclature from follicle center lymphoma to follicular lymphoma. The CAC overwhelmingly approved this proposal. For the rare case of purely diffuse lymphoma that seems to be of follicle center origin (predominance of centrocytes, rare centroblasts, BCL2 rearranged), the term follicle center lymphoma, diffuse, will be retained as a separate category. This diagnosis should only be made if both small and large cells are B cells and preferably with demonstration of some indicator of follicle center derivation, such as BCL2 rearrangement or CD10 expression (Table 8) .
Should follicular lymphoma be graded by the number of large cells? The following points were made. First, follicular lymphoma of grade 1 (follicular small cleaved) and grade 2 (follicular mixed) are more closely related to each other than to grade 3 follicular lymphoma (follicular large cell), since in sequential biopsies, transitions are seen from grade 1 (follicular small cleaved) to grade 2 (follicular mixed) and vice versa but rarely from grade 1 to grade 3 (follicular large cell). Second, patients with grade 3 tend to have earlier relapses (worse freedom from relapse) than do patients with grades 1 and 2 but similar overall survival, and this inferior freedom from relapse may be obliterated by doxorubicincontaining therapy. Third, grade 3 follicular lymphoma is not the same disease as diffuse large B-cell lymphoma (DLBCL) because it has a higher relapse rate, although it also has a slightly better overall survival. Finally, pathologists discriminate poorly between follicular lymphoma of grades 1 and 2, but they may be better able to discriminate between these and grade 3 cases. Several studies suggest that the Berard criteria 3 for the diagnosis of grade 3 follicular lymphoma (Ͼ 15 centroblasts/high-power field [hpf]) may best define the group of cases with a potential for early relapses that may be prevented by doxorubicin-containing chemotherapy. There was no consensus on whether this is warranted as initial therapy for these patients. It was also noted that factors other than histologic grade affect outcome in patients with follicular lymphoma, including clinical features summarized in the International Prognostic Index and potential biologic markers such as Bcl-2 protein expression and P53 mutations.
In summary, there was a consensus that follicular lymphoma should be categorized into at least two grades and that what is currently recognized as grade 3 (follicular large cell) should be discriminated from lower-grade cases. Although there are minor differences in natural history and response to treatment between grades 1 and 2 follicular lymphoma, there was a consensus that these did not mandate different approaches to treatment and thus were not of great clinical importance. Nonetheless, there was concern that changing the nomenclature would be potentially confusing and that a three-grade system should be retained. The pathologists were encouraged to define clinically relevant and reproducible criteria for such grading. After discussion, the pathologists concluded that since only the Berard cellcounting method has been repeatedly tested in the literature, it should be recommended for use (grade 1, zero to five centroblasts/ hpf; grade 2, six to 15 centroblasts/hpf; and grade 3, Ͼ 15 centroblasts/hpf). Ten to 20 hpfs, within different follicles, are counted; these are representative follicles, not those selected for having the most numerous large cells. 4 Should diffuse areas be reported? Several oncologists were of the opinion that diffuse areas in all grades of follicular lymphoma do seem to have an impact on prognosis. There was a consensus that diffuse areas should be reported and quantified according to the recommendations of the REAL classification, ie, predominantly follicular (Ͼ 75% follicular), follicular and diffuse (25% to 75% follicular), and predominantly diffuse (Ͻ 25% follicular 
Marginal Zone Lymphomas Should the term extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or MALT-type lymphoma be applied only to a lymphoma composed mostly of small cells? What should the terminology be for large-cell lymphoma in a MALT site?
The term high-grade MALT lymphoma, which is used by some pathologists to denote either transformation of a low-grade MALT lymphoma or any large B-cell lymphoma in a MALT site, is confusing to clinicians, who have come to regard the term MALT lymphoma to be synonymous with a lesion that may respond to antibiotic therapy for eradication of Helicobacter pylori. Because patients with a component of largecell lymphoma may not respond to antibiotic therapy, the oncologists were concerned that use of this term could result in undertreatment of extranodal large-cell lymphoma. Furthermore, recent data show that the types of cytogenetic abnormalities seen in low-grade MALT lymphomas differ from those seen in primary large-cell lymphoma of the stomach, raising the question of whether these primary lymphomas are really related to low-grade MALT lymphomas. Therefore, the oncologists preferred that the term MALT lymphoma be used only for the low-grade lymphoma originally described as low-grade B-cell lymphoma of MALT. Areas of large-cell lymphoma, if present, should be separately diagnosed as DLBCL. Primary large-cell lymphomas of MALT sites should be diagnosed as DLBCL, not as high-grade MALT lymphoma.
Should marginal zone/MALT lymphoma be graded by the proportion of large cells? The issue of grading MALT lymphoma has not been studied extensively. Several early reports suggested that cases with up to 25% large cells did not have a worse prognosis than cases with fewer large cells. However, a recent report of patients treated primarily with antibiotics found that the presence of increased transformed cells (5% to 10% with clusters of Ͻ 20 cells) conferred a slight but significantly worse prognosis compared with cases with less than 5% large cells. Cases with high-grade areas consisting of sheets of blasts (Ͼ 20 cells) behaved similarly to large-cell lymphoma with no low-grade component. In addition, it was reported at the meeting that the international non-Hodgkin's lymphoma classification project found that the presence of more than 5% large cells in an extranodal marginal zone lymphoma conferred a worse prognosis, as did areas of DLBCL. The consensus of the committee was that increased numbers of large cells may be of prognostic importance in MALT lymphoma and warrant further study. The WHO classification should specify criteria for grading so that its significance can be tested in future clinical studies. In cases of marginal zone B-cell lymphoma (low-grade MALT lymphoma) with coexisting DLBCL, a separate diagnosis of DLBCL should be made. The principle is therefore similar to that for follicular lymphoma: the tumors are graded according to the number of large cells, but when confluent areas of large cells are present, this indicates transformation to DLBCL.
Marginal zone lymphomas of nodal and splenic type: Are they ''real''? There was a consensus that recent data support the recognition that two other types of lymphoma, called marginal zone lymphomas, are distinct from MALT lymphoma and from each other. Splenic marginal zone lymphoma seems to be the tissue counterpart of splenic lymphoma with villous lymphocytes. Patients are typically older adults with bone marrow and blood involvement and an indolent clinical course. Nodal marginal zone lymphoma (which often has a prominent monocytoid B-cell component) must be distinguished from both MALT lymphoma with lymph node involvement and from other lymphomas (particularly follicular and mantle cell lymphoma) with a marginal zone pattern or a component of monocytoid B cells. Nodal marginal zone lymphoma seems to have a high rate of early relapse and overall survival similar to or slightly worse than that of follicular lymphoma.
Marginal Zone Lymphomas: Summary. 1. Should the term, extranodal marginal zone B-cell lymphoma of MALT or MALT-type lymphoma be applied only to a lymphoma composed mostly of small cells and not to large-cell lymphoma in a MALT site? YES 2. Should the term high-grade MALT lymphoma be used? NO • Suggested terminology: DLBCL (with or without areas of marginal zone/MALT-type lymphoma).
3. Should extranodal marginal zone B-cell lymphoma of MALT type be further graded/stratified based on the number of large cells? RESEARCH QUESTION • Criteria should be given so that additional studies can be conducted. 4. Are nodal and splenic marginal zone lymphoma distinct diseases that should be recognized and defined in the classification? YES
B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Are B-cell CLL and SLL one disease at different stages? As for the precursor neoplasms and Burkitt's lymphoma, the committee agreed with the pathologists that B-cell CLL and SLL are one disease at different stages, not two separate entities, and that they should be listed together in the classification.
Are cases of B-cell CLL with plasmacytoid differentiation (lymphoplasmacytoid immunocytoma in the Kiel classification) a different disease from typical CLL?
Data from several groups using the Kiel classification suggest that plasmacytoid differentiation may be an adverse prognostic factor in B-cell CLL; the committee concluded that the available data do not support calling it a different disease and that further study is needed to determine whether plasmacytoid differentiation is an adverse prognostic factor in CLL. Therefore, recognition of this feature is not required for diagnosis for clinical purposes, but criteria for diagnosing plasmacytoid differentiation should be agreed on, if possible, for future studies.
B-Cell CLL/SLL: Summary 1. Are B-cell CLL and SLL one disease at different stages? YES 2. Is plasmacytoid differentiation an indication of a different disease? NO 3. Is plasmacytoid differentiation a prognostic factor? RESEARCH QUESTION
Mantle-Cell Lymphoma
Should mantle-cell lymphoma be subclassified/graded for clinical purposes? A number of studies have found morphologic heterogeneity in mantle-cell lymphoma in both pattern and cytology and have suggested that some features may predict outcome. For example, cases with a mantle zone pattern have been less aggressive in some studies but not in others, and cases with blastic or blastoid morphology have had a worse prognosis in some reports. It was the consensus of the committee that, since no effective therapy currently exists for any type of mantle-cell lymphoma, stratification by morphologic features was not required for clinical diagnostic purposes at this time. However, the different cytologic types and patterns should be included in the WHO book on the classification, so that variant cases will be recognized as mantle-cell lymphoma for diagnosis and graded similarly for research studies.
Mantle-Cell Lymphoma: Summary. Should mantle-cell lymphoma be subclassified/graded for clinical purposes? By cytology? NO By pattern? NO
• Different cytologic types and patterns should be included so that they will be recognized as mantle-cell lymphoma for diagnosis and graded similarly for research.
Large B-Cell Lymphoma and Burkitt-Like Lymphoma
Should morphologic subclassification of DLBCL be required? There was a consensus on the part of the CAC that neither biologic nor clinical data at present support a requirement for subclassification of DLBCL according to the criteria of the Working Formulation or the Kiel classification. Data from the Kiel group suggest that immunoblastic lymphoma as defined in the updated Kiel classification (Ͼ 90% immunoblasts) has a worse prognosis than centroblastic lymphoma. Other data suggest that staining for bcl-6 (centroblastic) and syndecan-1/CD138 (immunoblastic) or evidence of BCL6 rearrangement (centroblastic) may help to discriminate between immunoblastic and centroblastic lymphoma. Nonetheless, neither reliable pathologic or biologic criteria for subclassification nor distinctive therapies that can be recommended for clinical practice are available at this time. For these reasons, the committee agreed that these categories should remain optional at this time. However, there was agreement that the pathologists should develop criteria for subclassification, so that these categories can be tested in future clinical studies ( The pathologists proposed to define Burkitt-like lymphoma as a subtype of large B-cell lymphoma. However, there was a clear consensus among the oncologists that this would be a mistake. Abundant data indicate that, in children, cases classified as Burkitt-like (or non-Burkitt) behave identically to Burkitt's lymphoma and would be undertreated if treated like large B-cell lymphoma. In adults, the biology of cases classified as Burkitt-like is less clear, but this may reflect the heterogeneity of the diagnostic criteria. In the international non-Hodgkin's lymphoma study, Burkitt-like was a nonreproducible category, with only about 50% agreement among the pathologists; the major areas of overlap were DLBCL and Burkitt's lymphoma. The oncologists urged that the category of Burkitt-like lymphoma be reserved for tumors that should be treated like Burkitt's lymphoma, ie, very high-grade tumors. The committee concluded that Burkitt-like lymphoma should be listed as a morphologic variant of Burkitt's lymphoma in the WHO classification. The term atypical Burkitt's lymphoma was proposed for this variant; however, the steering committee subsequently decided that the term Burkitt-like was preferable, since the relationship to Burkitt's lymphoma is not known in all cases. Thus, the category of Burkitt's lymphoma will include classic Burkitt's lymphoma and a variant, Burkitt-like lymphoma. In addition, three subcategories, ie, endemic, nonendemic, and immunodeficiency-associated, were proposed to reflect the major clinical and genetic subtypes of this disease (Table 10 ).
At present, there are no readily available immunophenotypic criteria that can be used in this differential diagnosis. However, participants observed that probably both the morphology and the biology of Burkitt's lymphoma are defined by the presence of c-myc rearrangement and overexpression, which results in all cells being perpetually in cycle. The gold standard for the diagnosis of Burkitt's lymphoma should be the presence of the translocation t(8;14)(q24;q32) and its variants or c-myc rearrangement. Cytogenetic analysis is recommended in all leukemic cases. If cytogenetic or Southern blot analysis is not available in solid tumors, it seems likely that the most reasonable surrogate for c-myc rearrangement is proliferation fraction. Therefore, it was suggested that, for cases in which cytogenetic analysis is not available, Burkitt's lymphoma or Burkitt-like lymphoma should not be diagnosed without a Ki-67 fraction close to 100%. Thus, the definition of Burkitt-like lymphoma is a lymphoma that morphologically resembles Burkitt's lymphoma but has more pleomorphism or large cells than classical Burkitt's lymphoma and, in addition, has a proliferation fraction of greater than 99%.
Do we need separate categories for clinical subtypes of DLBCL? There are multiple distinct clinical presentations of DLBCL, several of which have unique clinical behavior. These include mediastinal/thymic large B-cell lymphoma, primary CNS lymphoma, and primary effusion lymphoma. Of particular concern to pathologists is the category of cutaneous B-cell lymphomas, most of which have an indolent clinical course. Lymphomas in the marginal zone/ MALT lymphoma category are easily recognized by pathologists as low grade. However, the other major category, called cutaneous follicle center lymphoma in the recently proposed classification from the European Organization for Research and Treatment of Cancer, has a range of morphology, from a clearly low-grade lesion resembling nodal follicular lymphoma to a diffuse proliferation with numerous large cells that may be called DLBCL by pathologists. This type of lymphoma, which is typically localized to the head and trunk, responds well to local therapy (excision or radiation), and typically does not disseminate to lymph nodes, comprised 70% of cutaneous B-cell lymphomas in the European Organization for Research and Treatment of Cancer study. There is concern that if the distinctive histologic and clinical features of cutaneous follicle center lymphoma are not recognized by both pathologists and oncologists, these patients will be overtreated with aggressive chemotherapy.
The consensus of the committee was that separate classifications of lymphomas at specific extranodal sites are not needed for clinical purposes. However, the site of involvement should be clearly stated in the pathology report, and oncologists are obliged to understand the distinctive clinical features of lymphomas at various sites. Distinct entities, such as primary mediastinal (thymic) B-cell lymphoma, primary effusion lymphoma, and intravascular lymphoma, should be described in the WHO book 2 and listed as subtypes of DLBCL (Table 10 ). The committee recommended that the distinctive clinical features of B-cell lymphomas in the skin be indicated in the descriptions of each lymphoma subtype (Table 8) .
Large patients. The recently described primary effusion lymphoma, which was initially thought to be unique to HIV ϩ patients, has been reported in HIV Ϫ patients as well. T-cell lymphomas in HIV ϩ patients also do not seem to be distinctive. A recently described plasmablastic lymphoma is distinctive, and its relationship to myeloma remains to be determined.
The polymorphic posttransplant lymphoproliferative disorders seem to be a unique form of lymphoproliferation that does not occur in immunologically normal individuals. It was suggested that EBNA-2 expression in these lesions indicates that the proliferation is EBV-driven and may respond to reduced immunosuppression.
In summary, the committee suggested that a separate classification was not needed for immunodeficiencyassociated lymphomas but that the specific types of lymphomas that occur in immunodeficiency states and their distinctive features in these conditions should be indicated in the WHO book. 2 In addition, the pathologists thought that a separate classification of posttransplant lymphoproliferative disorders would be useful, because of their distinctive biologic and clinical features (Table 3) .
Lymphomas in Immunodeficiency States: Summary. Do we need a separate classification? NO
• Note the frequency of specific types in immunodeficiency states.
• Posttransplant lymphoproliferative disorders are distinctive and need a separate classification.
• EBV status may be important in determining prognosis and treatment.
Peripheral T/NK-Cell Neoplasms
Are clinical syndromes integral to the definition of T-/NKcell neoplasms? Many distinct T-cell and/or NK-cell diseases vary in cytologic composition (small to large to anaplastic). Immunophenotypic variation exists within disease entities, and many antigens are shared by different diseases. Specific cytogenetic features are not defined for most entities, and even T-cell receptor types (alpha-beta v gamma-delta) or T versus NK lineage are not sufficient to define distinct disease entities. To a greater extent than is appreciated for B-cell neoplasms, it seems that clinical syndromes, and particularly location (nodal v extranodal and specific extranodal sites), are important in determining the biologic behavior of the disease. The committee agreed that clinical syndromes seem to be integral to the definition of Tand NK-cell neoplasms.
Should peripheral T-cell lymphoma, unspecified, be subclassified (according to the Kiel classification) for clinical purposes? According to the available data, there seems to be no immediate justification or clear criteria for recognizing cytologic subtypes within the broad category of peripheral T-cell lymphoma, unspecified. However, given the marked differences in clinical behavior between primary extranodal T-/NK-cell lymphomas and primary nodal lymphomas, it is likely to be clinically relevant to subdivide the unspecified category into nodal and extranodal types. Both pathologists and oncologists will need to continue to address this area in further studies (Tables 14 and 15) .
Peripheral T-/NK-Cell Lymphomas: Summary. There is evidence that most cases of ALCL of T-cell type presenting with disease localized to the skin are different from systemic ALCL: the clinical course is indolent, they lack the translocation t(2;5)(p23;q35), are ALK protein-negative, and seem to form a spectrum with lymphomatoid papulosis. Although some members of the committee held that the clinical course was not predictably indolent, there was general agreement that, at least for the purposes of further study, cutaneous and systemic ALCL should be considered distinct categories. There was significant concern, however, about the proposed term primary CD30 ϩ cutaneous lymphoproliferative disorder, a term that includes lymphomatoid papulosis, cutaneous ALCL, and CD30 ϩ cutaneous T-cell lymphomas that do not have typical anaplastic morphology. Oncologists thought that including lymphomatoid papulosis in a classification of lymphomas would imply to patients and insurers that this is a malignancy, whereas it typically has a benign clinical course.
In conclusion, the committee agreed that primary cutaneous ALCL should be included in the list of neoplasms and that a discussion of CD30 ϩ cutaneous lymphoproliferative diseases should be included in the WHO book 2 with a discussion of lymphomatoid papulosis and borderline lesions. Because it is difficult to predict using morphology alone which disease the patient has, pathologists will often be forced to use the term CD30 ϩ cutaneous lymphoproliferative disease on the pathology reports, with the understanding that clinical criteria must be added to determine whether the patient has a locally progressive disease that requires treatment (ALCL) or a relapsing condition that needs no treatment (lymphomatoid papulosis).
What is the gold standard for defining ALCL? Given the recent availability of an antibody to the ALK protein, which is highly associated with the translocation t(2;5)(p23;q35), the question was raised whether this can be used as the
CLINICAL GROUPINGS OF B-AND T-/NK-CELL LYMPHOMAS
Are Clinical Groupings Useful for Clinical Practice?
The committee concluded that grouping the B-and T-/NK-cell neoplasms into prognostic categories would serve no clear purpose and could hamper understanding of the specific features of some of the diseases. There are no groups of diseases that require identical treatment, and if treatment must be individualized to a specific disease, grouping serves no purpose and may be misleading. The entities listed in the classification are clearly defined and clinically relevant, and it is necessary for oncologists and pathologists dealing with these diseases to understand each of them.
Is a Shorter List of Diseases Necessary for Clinicians?
The committee also discussed whether a shorter list of common diseases should be prepared for clinical use. There was a clear consensus that the complete list of neoplasms should have more common entities highlighted, to draw the attention of nonexperts to the diseases they are likely to encounter in practice. Opinion was split on the need for a short list, and a poll taken after the meeting showed a majority of the oncologists favored one comprehensive list with common entities highlighted.
Clinical Groupings of Lymphoid Neoplasms: Summary 1. Are clinical groupings necessary or useful? NO 2. Should common entities be indicated in bold? YES 3. Should a short list of common entities be included for clinicians? NO
UNCLASSIFIABLE HEMATOLOGIC MALIGNANCIES
Even with the advances in immunophenotyping and genetic analysis, some hematologic malignancies still defy classification. A case may be unclassifiable because of an inadequate tissue sample, because special studies are not available, because the tissue is poorly preserved, or because even with complete analysis it does not fit into one of the categories recognized in the classification. For each case, the reason for the inability to classify it should be stated in thepathology report. Suggested categories and terminology for unclassifiable cases are listed in Table 16 .
CONCLUSION
The committee concluded that the approach to the classification of hematologic malignancies proposed by the International Lymphoma Study Group in the REAL classification and adopted now in the WHO classification represents a significant advance in our ability to identify and treat specific disease entities. This approach leaves room for identifying new entities and subtypes and for incorporating new data into diagnostic criteria, disease definition, and nomenclature. It has also produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world that should facilitate accumulation of new knowledge, and which will hopefully continue in the future. After the WHO classification is completed, it will be important to develop a mechanism for updating it, to avoid the confusion that has often resulted in the past from the existence of multiple classifications.
